Cybin has filed two international patent applications to support its psychedelic research phases programmes.
Biotechnology company, Cybin Inc., which is focused on progressing psychedelic therapeutics, has filed two international patent applications that bring the potential to obtain patent coverage in 153 countries for each of the applications.
Cybin says the applications will strengthen its CYB005 programme directed to therapy-resistant psychiatric disorders, and provide compositions for further evaluation in additional future research programmes.
The patents
The patent application, governed by the Patent Cooperation Treaty (PCT), would give Cybin the right to file future national applications into treaty member jurisdictions and claim a library of phenethylamine and derivative drug development candidates and methods of use.
One of the applications claims a group of proprietary compounds identified by Cybin’s research data as being important for further evaluation toward selection as potential therapeutics, and the other includes claims and disclosures toward several other proprietary novel psychedelic compounds, including compounds with positive research data.
Cybin CEO Doug Drysdale, said: “Cybin is dedicated to finding treatments for therapy-resistant psychiatric indications as we believe these will provide patients and their medical providers with new avenues to address this significant unmet need.
“We appreciate the continued dedication of our team to identify and progress our research phase programs toward pre-clinical evaluation.”
Currently, Cybin’s indications include major depressive disorder (CYB001), alcohol use disorder (CYB003) and anxiety disorders (CYB004) and two programmes in the research phase (CYB005 and CYB006) which involve synthesis and testing of more than 50 novel compounds coupled with extensive in vitro and in vivo pharmacokinetic, receptor binding, behavioural and safety evaluations.
